UA105384C2 - Лечение нарушений, связанных с инсулинорезистентностью - Google Patents

Лечение нарушений, связанных с инсулинорезистентностью

Info

Publication number
UA105384C2
UA105384C2 UAA201112634A UAA201112634A UA105384C2 UA 105384 C2 UA105384 C2 UA 105384C2 UA A201112634 A UAA201112634 A UA A201112634A UA A201112634 A UAA201112634 A UA A201112634A UA 105384 C2 UA105384 C2 UA 105384C2
Authority
UA
Ukraine
Prior art keywords
insulin
treatment
resistant disorders
disorders
resistant
Prior art date
Application number
UAA201112634A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Ганеш А. КОЛУМАМ
Янь ХУ (Хелен)
Веньцзюнь Оуян
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA105384(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of UA105384C2 publication Critical patent/UA105384C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201112634A 2009-04-01 2010-03-30 Лечение нарушений, связанных с инсулинорезистентностью UA105384C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16567709P 2009-04-01 2009-04-01
PCT/US2010/029280 WO2010114859A1 (en) 2009-04-01 2010-03-30 Treatment of insulin-resistant disorders

Publications (1)

Publication Number Publication Date
UA105384C2 true UA105384C2 (ru) 2014-05-12

Family

ID=42229822

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201112634A UA105384C2 (ru) 2009-04-01 2010-03-30 Лечение нарушений, связанных с инсулинорезистентностью

Country Status (24)

Country Link
US (1) US20100266595A1 (enExample)
EP (1) EP2413967A1 (enExample)
JP (1) JP5795306B2 (enExample)
KR (1) KR101766927B1 (enExample)
CN (1) CN102448493B (enExample)
AR (1) AR075998A1 (enExample)
AU (1) AU2010232692C1 (enExample)
BR (1) BRPI1011535A2 (enExample)
CA (1) CA2752908A1 (enExample)
CL (1) CL2011002416A1 (enExample)
CO (1) CO6410313A2 (enExample)
CR (1) CR20110552A (enExample)
EC (1) ECSP11011429A (enExample)
IL (1) IL214745A0 (enExample)
MA (1) MA33248B1 (enExample)
MX (1) MX347978B (enExample)
NZ (1) NZ595005A (enExample)
PE (1) PE20120628A1 (enExample)
RU (1) RU2537142C2 (enExample)
SG (1) SG174891A1 (enExample)
TW (1) TWI474833B (enExample)
UA (1) UA105384C2 (enExample)
WO (1) WO2010114859A1 (enExample)
ZA (1) ZA201106076B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1482920B2 (en) * 2002-02-12 2011-07-20 Hunza di Pistolesi Elvira & C. S.a.S. Compositions containing n-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids
BRPI0908312A2 (pt) 2008-05-05 2015-08-18 Novimmune Sa '' anticorpo monoclonal totalmente humano isolado, composição farmacêutica, método de alívio de um sintoma de uma indicação clínica e método de alívio de um sintoma de uma doença autoimune, distúrbio inflamatório ou distúrbio da proliferação celular''
US8790642B2 (en) 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
EP3214442A1 (en) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Treatment of gastrointestinal inflammation and psoriasis and asthmainflammation and psoriasis a
US9117641B2 (en) 2012-10-29 2015-08-25 Perkinelmer Health Sciences, Inc. Direct sample analysis device adapters and methods of using them
PT2950780T (pt) * 2013-02-04 2020-07-07 Sanofi Sa Formulações farmacêuticas estabilizadas de análogos de insulina e/ou derivados de insulina
TWI780236B (zh) * 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
KR102321861B1 (ko) 2017-03-10 2021-11-05 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 Il-17a 및 il-17f 모두에 대한 단일클론 항체 및 이의 용도

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5266561A (en) 1988-01-11 1993-11-30 Amylin Pharmaceuticals, Inc. Treatment of type 2 diabetes mellitus
WO1990001038A1 (en) 1988-07-20 1990-02-08 Nordisk Gentofte A/S Human insulin analogs and preparations containing them
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992020373A1 (en) 1991-05-14 1992-11-26 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
CA2147180A1 (en) 1992-10-15 1994-04-28 Gokhan S. Hotamisligil Treatment of insulin resistance in obesity linked type ii diabetes using antagonists to tnf-.alpha. function
US5527307A (en) 1994-04-01 1996-06-18 Minimed Inc. Implantable medication infusion pump with discharge side port
US5569186A (en) 1994-04-25 1996-10-29 Minimed Inc. Closed loop infusion pump system with removable glucose sensor
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
US5939269A (en) 1994-12-28 1999-08-17 The Regents Of The University Of California Antagonists to insulin receptor tyrosine kinase inhibitor
US5637095A (en) 1995-01-13 1997-06-10 Minimed Inc. Medication infusion pump with flexible drive plunger
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
NZ314406A (en) 1996-03-18 2000-12-22 Sankyo Co Treatment or prophylaxis of pancreatitis with a medicament containing an insulin sensitiser including oxazoles and thiazoles
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US20020177188A1 (en) 1998-05-15 2002-11-28 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6040292A (en) 1999-06-04 2000-03-21 Celtrix Pharmaceuticals, Inc. Methods for treating diabetes
US6187333B1 (en) 1999-09-20 2001-02-13 Diabex, Inc. Method for treating, controlling, and preventing diabetes mellitus
ES2333772T3 (es) 1999-12-23 2010-03-01 Genentech, Inc. Polipeptidos homologos de il-17 y il-17r y sus utilizaciones terapeuticas.
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
CA2461818A1 (en) 2001-10-15 2003-04-24 Genentech, Inc. Treatment and diagnosis of insulin resistant states
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
DE602005013805D1 (de) * 2004-09-21 2009-05-20 Merck Serono Sa Coinsins Verwendung von il-17f zur behandlung und/oder prävention von neurologischen erkrankungen
DE602006009834D1 (de) * 2005-09-01 2009-11-26 Schering Corp Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
US7790163B2 (en) * 2006-03-10 2010-09-07 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
US7910703B2 (en) * 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
TW200902064A (en) * 2007-03-28 2009-01-16 Wyeth Corp Methods and compositions for modulating IL-17F/IL-17A biological activity
AU2007352412B2 (en) * 2007-04-27 2013-05-16 Zymogenetics, Inc. Antibodies that bind both IL-17A and IL-17F and methods of using the same
ES2465223T3 (es) * 2007-04-27 2014-06-05 Zymogenetics, Inc. Antagonistas de IL-17A, IL-17F e IL-23P19 y procedimientos de uso
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists
WO2009043171A1 (en) * 2007-10-02 2009-04-09 Institut National De La Recherche Scientifique Method of regulating the th17 pathway and its associated metabolic impact

Also Published As

Publication number Publication date
JP2012522788A (ja) 2012-09-27
MX2011010273A (es) 2011-10-17
TW201038284A (en) 2010-11-01
AR075998A1 (es) 2011-05-11
RU2011144122A (ru) 2013-05-10
BRPI1011535A2 (pt) 2016-03-29
KR20120005483A (ko) 2012-01-16
CN102448493B (zh) 2014-04-30
US20100266595A1 (en) 2010-10-21
CR20110552A (es) 2011-12-07
ECSP11011429A (es) 2011-12-30
AU2010232692C1 (en) 2017-06-01
CO6410313A2 (es) 2012-03-30
ZA201106076B (en) 2012-11-28
JP5795306B2 (ja) 2015-10-14
PE20120628A1 (es) 2012-05-26
AU2010232692B2 (en) 2016-12-01
NZ595005A (en) 2014-04-30
WO2010114859A1 (en) 2010-10-07
KR101766927B1 (ko) 2017-08-09
IL214745A0 (en) 2011-11-30
AU2010232692A1 (en) 2011-09-08
TWI474833B (zh) 2015-03-01
SG174891A1 (en) 2011-11-28
MA33248B1 (fr) 2012-05-02
CL2011002416A1 (es) 2012-04-20
CN102448493A (zh) 2012-05-09
EP2413967A1 (en) 2012-02-08
RU2537142C2 (ru) 2014-12-27
CA2752908A1 (en) 2010-10-07
MX347978B (es) 2017-05-22

Similar Documents

Publication Publication Date Title
MX347978B (es) Uso de los anticuerpos anti-il-17a y anti-il-17f en el tratamiento de la resistentes a insulina.
JO2576B1 (en) Antibodies
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
MX2010003574A (es) Anticuerpos il-23.
MX2009003973A (es) Moleculas de anticuerpo que unen il-17 e il-17f.
MX2011011729A (es) Anticuerpo anti il-17f y metodos de uso de los mismos.
MX355256B (es) Anticuerpos anti-il-17a/il-17f de reactividad cruzada y métodos de uso de los mismos.
PH12012500862B1 (en) Il-17a antagonists
JO3469B1 (ar) طافرات fgf21 واستخداماتها
UA96141C2 (ru) Нейтрализующее антитело, которое имеет специфичность к человеческому il-6
NZ599875A (en) Human il-23 antigen binding proteins
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY156315A (en) Anti-vegf antibodies
MX342810B (es) Anticuerpos del receptor anti-interleucina-6 (anti-il-6) y sus metodos de uso.
DOP2010000369A (es) Inmunoglobulinas con dominio variable dual y usos de la misma
TN2013000292A1 (en) Antibody molecules which bind il-17a and il-17f
CA2894869C (en) Solution formulations of engineered anti-il-23p19 antibodies
SG10201903166PA (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA201101241A1 (ru) Лечение лейкозов и хронических миелопролиферативных болезней антителами к ерна3
WO2007025977A8 (en) Anti-tnf alpha producing lactic acid bacteria for the treatment of chronic enterocolitis
SG179135A1 (en) Methods for treating psoriasis
UA105073C2 (uk) Антитіло проти фракталкіну, композиція і спосіб для лікування запальних порушень
UA99716C2 (ru) Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
PH12013500432A1 (en) Anti-vegfr-3 antibody compositions
TH152420A (th) การรักษาความผิดปกติจากภาวะดื้อต่ออินซูลิน